Cryptococcosis in Patients With Cirrhosis of the Liver and Posttransplant Outcomes
Nina Singh,Costi D Sifri,Fernanda P Silveira,Rachel Miller,Kevin S Gregg,Shirish Huprikar,Erika D Lease,Andrea Zimmer,J Stephen Dummer,Cedric W Spak,Christine Koval,David B Banach,Miloni Shroff,Jade Le,Darin Ostrander,Robin Avery,Albert Eid,Raymund R Razonable,Jose Montero,Emily Blumberg,Ahlaam Alynbiawi,Michele I Morris,Henry B Randall,George Alangaden,Jeffrey Tessier,Marilyn M Wagener,Hsin Yun Sun
DOI: https://doi.org/10.1097/TP.0000000000000690
Transplantation
Abstract:Background: The outcomes and optimal management of cirrhotic patients who develop cryptococcosis before transplantation are not fully known. Methods: We conducted a multicenter study involving consecutive patients with cirrhosis and cryptococcosis between January 2000 and March 2014. Data collected were generated as standard of care. Results: In all, 112 patients were followed until death or up to 9 years. Disseminated disease and fungemia were present in 76.8% (86/112) and 90-day mortality was 57.1% (64/112). Of the 39 patients listed for transplant, 20.5% (8) underwent liver transplantation, including 2 with active but unrecognized disease before transplantation. Median duration of pretransplant antifungal therapy and posttransplant therapy was 43 days (interquartile range, 8-130 days) and 272 days (interquartile range, 180-630 days), respectively. Transplantation was associated with lower mortality (P = 0.002). None of the transplant recipients developed disease progression during the median follow-up of 3.5 years with a survival rate of 87.5%. Conclusions: Cryptococcosis in patients with cirrhosis has grave prognosis. Our findings suggest that transplantation after recent cryptococcal disease may not be a categorical exclusion and may be cautiously undertaken in liver transplant candidates who are otherwise deemed clinically stable.